menu
    • menu

    Company profile for Outlook Therapeutics

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are advancing ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD, DME and BRVO. Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications. Our goal is to launch ONS-5010 as the first and only approved ophthalmic formulation of bevacizumab in the United Stat...
    We are advancing ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD, DME and BRVO. Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications. Our goal is to launch ONS-5010 as the first and only approved ophthalmic formulation of bevacizumab in the United States, Europe, Japan and other markets for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Outlook TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    7 Clarke Drive Cranbury, New Jersey 08512
    Telephone
    Telephone
    609.619.3990
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://outlooktherapeutics.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/outlook-therapeutics
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Outlook Therapeutics Finalizes $5.0M Direct Offering Close
    Outlook Therapeutics Finalizes $5.0M Direct Offering Close

    23 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7205711

    FIRSTWORD PHARMA
    23 Apr 2026
    Share Share
    Outlook Therapeutics Finalizes $5.0M Public Offering
    Outlook Therapeutics Finalizes $5.0M Public Offering

    25 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/25/3262571/0/en/Outlook-Therapeutics-Announces-Closing-of-5-0-Million-Public-Offering.html

    GLOBENEWSWIRE
    25 Mar 2026
    Share Share
    Outlook Therapeutics Prices $5M Public Offering
    Outlook Therapeutics Prices $5M Public Offering

    24 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/24/3261063/0/en/Outlook-Therapeutics-Announces-Pricing-of-5-0-Million-Public-Offering.html

    GLOBENEWSWIRE
    24 Mar 2026
    Share Share
    Outlook Therapeutics Announces Proposed Public Offering
    Outlook Therapeutics Announces Proposed Public Offering

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260887/0/en/Outlook-Therapeutics-Announces-Proposed-Public-Offering.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    Outlook Therapeutics Unveils $18.4M Non-Convertible Note
    Outlook Therapeutics Unveils $18.4M Non-Convertible Note

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256238/0/en/Outlook-Therapeutics-Announces-New-18-4-Million-Non-Convertible-Note-Financing-and-Amendment-to-Existing-Convertible-Note.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Outlook Updates On FDA Meeting Regarding ONS-5010/LYTENAVA
    Outlook Updates On FDA Meeting Regarding ONS-5010/LYTENAVA

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250685/0/en/Outlook-Therapeutics-Provides-Update-Following-Type-A-Meeting-with-FDA-Regarding-ONS-5010-LYTENAVA-bevacizumab-vikg.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search